FoRx Therapeutics is an incorporated privately held drug discovery company based in Basel, Switzerland. The company is active in oncology and focuses on drugging key molecular targets involved in the DNA replication stress pathway. This constitutes a novel and promising approach in the development of next-generation anti-cancer drugs. FoRx Therapeutics is backed by a syndicate of investors that include EQT Life Sciences, Novartis Venture Fund, Pfizer Ventures, M Ventures and Omega Funds.